Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole + Ablation for High-risk Barrett's Esophagus
NCT06732388Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2026
- Primary completion
- Aug 2030
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Barrett's esophagus comparing Group I (itraconazole) with Group II (placebo) (2 arms). Primary endpoint: Time to complete eradication of intestinal metaplasia up to 12 weeks. Started Jun 2026; status: recruiting.
02
Drugs
itraconazole
03
Conditions
Barrett's esophagus
Beyond the preview
Go deeper on NCT06732388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732388.